A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus

The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.

Inclusion Criteria:

• patients in advanced stage of malignant tumor diagnosticated by pathologic and cytological analysis.
• lack of routine effective treatment,failure of routine treatment or relapse
• age of 18-70,ECOG 0-2 and estimated survival is above 3 months
• had an interval of above 4 weeks since exposure to chemotherapy or radiotherapy and above 6 weeks since exposure to nitrosoureas or mitomycin C.

Exclusion Criteria:

• Serious internal diseases
• uncontrolled primary and metastatic brain tumor
• sizes of tumor does not meet the requirement of injection